Cue Biopharma (CUE) Current Deferred Revenue (2017 - 2018)
Cue Biopharma (CUE) posted Current Deferred Revenue of $381465.0 for Q4 2018, up 69.54% sequentially from $225000.0 in Q3 2018, and up 949.02% YoY from $36364.0 in Q4 2017.
Cue Biopharma (CUE) Current Deferred Revenue (2017 - 2018) Analysis & Trends
Cue Biopharma has reported Current Deferred Revenue for 2 years, with the latest figure at $381465.0 in Q4 2018.
- Quarterly Current Deferred Revenue rose 949.02% year-over-year to $381465.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $381465.0 (up 949.02% YoY) and the FY2018 annual result came in at $381465.0, up 949.02% from the prior year.
- Current Deferred Revenue rose to $381465.0 in Q4 2018 per CUE's latest filing, from $225000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $381465.0 in Q4 2018 and troughed at $36364.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 381,465.00 |
| Sep 30, 2018 | 225,000.00 |
| Jun 30, 2018 | 75,000.00 |
| Dec 31, 2017 | 36,364.00 |